NCT03516214View on ClinicalTrials.gov

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

November 27, 2023

Conditions
Bronchial Neoplasms
Interventions
DRUG

EGF816

Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.

DRUG

Trametinib

Continuous oral treatment (once daily) with the MEK inhibitor trametinib.

Trial Locations (7)

Unknown

University Hospital of Cologne, Cologne

University Hospital Dresden, Dresden

University Hospital Essen, Essen

University Hospital Frankfurt, Frankfurt

University Hospital Würzburg, Würzburg

Vall d'Hebron University Hospital, Barcelona

08028

Instituto Oncológico Dr. Rosell, Barcelona

All Listed Sponsors
lead

University of Cologne

OTHER

NCT03516214 - EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations | Biotech Hunter | Biotech Hunter